Crossmark

Prognostic impact of rapid reduction of involved free light chains in multiple myeloma patients under first-line treatment with Bendamustine, Prednisone, and Bortezomib (BPV)

Crossref DOI link: https://doi.org/10.1007/s00432-020-03504-3

Published Online: 2021-01-12

Published Print: 2021-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Holzhey, Tanja

Pönisch, Wolfram https://orcid.org/0000-0002-9666-6274
Wang, Song-Yau

Holzvogt, Madlen

Holzvogt, Bruno

Andrea, Marc

Zehrfeld, Thomas

Hammerschmidt, Doreen

Hoffmann, Franz Albert

Becker, Cornelia

Schwarzer, Andreas

Schwarz, Maik

Schönfelder-Fricke, Uta

Edelmann, Thomas

Braunert, Leanthe

Franke, Georg-Nikolaus

Jentzsch, Madlen

Schwind, Sebastian

Bill, Markus

Grimm, Juliane

Remane, Yvonne

Platzbecker, Uwe

Scholz, Markus
Funding

Funding for this research was provided by:

Projekt DEAL
License Information

Text and Data Mining valid from 2021-01-12

Version of Record valid from 2021-01-12
More Information

Article History

Received: 16 September 2020

Accepted: 12 December 2020

First Online: 12 January 2021

Compliance with ethical standards

:

: All authors declare neither financial or nonfinancial interests that may be relevant to the submitted work.

Document is current

Any future updates will be listed below